CONTENTS

I. Acknowledgement ................................................................. i
II. Abbreviation/Acronym ........................................................... iii

CHAPTER 1: INTRODUCTION

1.1 Introduction ............................................................................. 01

CHAPTER 2: REVIEW OF LITERATURE

2.1 History of Leprosy................................................................. 06
  2.1.1 Origin and spread of leprosy ........................................... 06
  2.1.2 Epidemiology ........................................................................ 07
    2.1.2.1 Leprosy situation in India ........................................... 08
  2.1.3 Diagnosis of leprosy ......................................................... 12
  2.1.4 Classification of the leprosy disease spectrum .................. 13
    2.1.4.1 Leprosy reactions .................................................. 16
    2.1.4.2 Lucio Phenomenon (Erythema Necroticans) ................. 17
  2.1.5 Transmission of leprosy .................................................... 17
  2.1.6 Mycobacterium leprae, the etiologic agent of leprosy ........ 19
    2.1.6.1 Basic characteristics .............................................. 19
    2.1.6.2 Genome and proteome ........................................... 22
  2.1.7 Treatment ................................................................. 23
    2.1.7.1 Dapsone .............................................................. 25
    2.1.7.2 Rifampicin ............................................................ 25
    2.1.7.3 Clofazimine .......................................................... 26
    2.1.7.4 Ofloxacin .............................................................. 27
    2.1.7.5 Minocycline .......................................................... 27
  2.1.8 Vaccination ................................................................. 28
    2.1.8.1 Lacunae in leprosy vaccine studies ......................... 28
  2.2 Immunology ................................................................. 29
    2.2.1 Innate immunity .......................................................... 29
    2.2.1.1 Receptors of innate immunity ................................... 31
    2.2.1.2 Alternative mechanism of infection ......................... 33
    2.2.2 Adaptive immunity: Development of cell-mediated immunity 33
    2.2.2.1 Role of T lymphocyte subset in leprosy .................... 33
    2.2.2.2 Neutrophil recruitment ......................................... 35
  2.2.3 Cytokines in leprosy ....................................................... 36
    Mechanism of nerve injury .................................................. 37
  2.3 Genetic susceptibility and infectious disease ...................... 38
    2.3.1 Assessing the genetic contribution to leprosy risk ........... 40
    2.3.2 Study design for complex diseases ............................... 42
      2.3.2.1 Linkage studies .................................................. 43
CHAPTER 3: MATERIALS AND METHODS

3.1 Study subjects: Cases and Controls

3.1.1 Details of North India Leprosy patients
3.1.2 Details of East India-Orissa Leprosy patients

3.2 High molecular weight genomic DNA isolation

3.2.1 Genomic DNA isolation from peripheral blood
3.2.2 Quantitation of genomic DNA
3.2.3 Agarose gel electrophoresis

3.3 Polymorphism study of the selected regions of candidate genes

3.3.1 SNP Selection
3.3.2 High throughput genotyping of SNPs in the candidate genes using Sequenom MassArray
3.3.2.1 Plex designing
3.3.2.2 Initial PCR
3.3.2.3 SAP treatment
3.3.2.4 iPLEX PCR
3.3.2.5 Dispensing onto SpectroCHIP Arrays, Chip reading and Data analysis

3.3.3 Polymerase chain reaction (PCR)
3.3.4 Automated DNA sequencing

3.4 Cloning of SNPs present in promoter and enhancer region of PARK2 and PACRG Gene

3.4.1 Elution of DNA fragment from agarose gel
3.4.2 pGL3 cloning
3.4.3 Competent cell preparation
3.4.4 Transformation
3.4.5 Single colony PCR
3.4.6 Mini-preparation of plasmid DNA
3.4.7 Site directed mutagenesis
3.4.8 In vitro characterisation of cloned regions
3.4.8.1 Cell culture
3.4.8.2 Transient transfection and luciferase assays

3.5 Statistical analysis

CHAPTER 4: RESULTS

4.1 Genetic variations in PARK2 and PACRG gene regulatory regions and their interaction with important immuno-regulatory genes in the outcome of leprosy
4.1.1 Association of SNP variants within PARK2-PACRG gene regulatory regions with leprosy susceptibility............................................................... 78
4.1.2 Detailed results of chosen SNPs and their significant association with leprosy............................................................. 82
  4.1.2.1 Details of the significant SNPs of PARK2 and PACRG gene regulatory........................................................................ 100
  4.1.2.2 LD and BIN structures of studied SNPs of PARK2 and PACRG gene regulatory region in Indian population groups........... 111
  4.1.2.3 Haplotype analysis of the significant associated SNPs in the PARK2 and PACRG gene regulatory region........................ 112
  4.1.2.4 Evolutionary conservation of the SNPs ..................................... 117
  4.1.2.5 Bio-informatics analysis.............................................................. 117
  4.1.2.6 Functional relevance of associated SNPs .................................. 120
4.2 Interaction analysis with immune-regulatory genes ......................... 122
  4.2.1 Interaction analysis of PARK2 regulatory region SNPs with anti-inflammatory cytokines............................................. 122
  4.2.2 Interaction analysis of PARK2 regulatory region SNPs with pro-inflammatory cytokines and genes spanning 6p21.3 chromosomal region................................................................. 125
  4.2.3 Interaction analysis of PARK2 gene regulatory region SNPs with the genes providing protection or risk towards leprosy........... 128

CHAPTER 5: DISCUSSION

5.1 Association of SNP variants along 6q26 region with leprosy susceptibility...... 131
5.2 Interaction analysis of PARK2 gene regulatory region variant with important immune-regulatory genes........................................ 135

CONCLUSIONS............................................................................................... 138
REFERENCES ................................................................................................ 140
PUBLICATIONS ............................................................................................ 155